<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00009555</url>
  </required_header>
  <id_info>
    <org_study_id>A5079</org_study_id>
    <secondary_id>10175</secondary_id>
    <secondary_id>ACTG A5079</secondary_id>
    <secondary_id>AACTG A5079</secondary_id>
    <nct_id>NCT00009555</nct_id>
  </id_info>
  <brief_title>Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Placebo-Controlled Trial of Physiologic Testosterone Supplementation for HIV-Positive Men With Mildly to Moderately Reduced Serum Testosterone Levels and Abdominal Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if treatment with testosterone will reduce abdominal fat&#xD;
      in HIV-positive men.&#xD;
&#xD;
      Many HIV patients on antiretroviral therapy show an increase in abdominal fat. Studies have&#xD;
      shown that treatment with testosterone may decrease abdominal fat. This study will determine&#xD;
      if testosterone will reduce abdominal fat in HIV patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reports suggest that many HIV-infected patients on antiretroviral therapy experience an&#xD;
      increase in abdominal fat. The mechanisms of abdominal fat accumulation in HIV-infected&#xD;
      patients are not known. Studies have shown: treatment with testosterone gel reduces total&#xD;
      body fat in young, androgen-deficient men; testosterone replacement in middle-aged men with&#xD;
      mid-segment obesity decreases visceral fat; and replacement doses of testosterone decrease&#xD;
      fat mass and augment lean body mass in HIV-infected men with androgen deficiency. Therefore,&#xD;
      there is a strong rationale for evaluating the effectiveness of testosterone replacement in&#xD;
      HIV-infected men with visceral obesity and low testosterone levels.&#xD;
&#xD;
      Patients are stratified based on their viral load. Patients receive either testosterone gel&#xD;
      or placebo applied to the skin once daily for 24 weeks. Patients remain on their current&#xD;
      antiretroviral regimens, which are not supplied through the study. Patients who receive&#xD;
      testosterone during the first 24 weeks are eligible to receive it for an additional 24 weeks.&#xD;
      Patients on placebo are followed for an additional 24 weeks. Clinical and laboratory&#xD;
      evaluations for visceral fat changes are performed throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">March 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>86</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients may be eligible for this study if they:&#xD;
&#xD;
          -  Are HIV-positive.&#xD;
&#xD;
          -  Have been taking anti-HIV medications for at least 12 weeks before study entry and&#xD;
             plan to continue taking them for an additional 24 weeks.&#xD;
&#xD;
          -  Are male and between 18 and 70 years old.&#xD;
&#xD;
          -  Have a measurement of greater than 100 cm around the abdomen.&#xD;
&#xD;
          -  Can report an increase in abdominal size after taking antiretroviral drugs.&#xD;
&#xD;
          -  Have a viral load less than 10,000 copies/ml within 6 weeks prior to screening.&#xD;
&#xD;
          -  Have a serum total testosterone between 125 and 400 ng/dl. If serum total testosterone&#xD;
             is greater than 400 ng/dl, bioavailable testosterone must be less than 115 ng/dl or&#xD;
             free testosterone must be less than 50 pg/ml.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients will not be eligible for this study if they:&#xD;
&#xD;
          -  Take certain drugs, including testosterone derivatives, glucocorticoids, appetite&#xD;
             stimulants, dronabinol, megestrol acetate, androstenediols, oxandrolone, or other&#xD;
             anabolic agents such as dehydroepiandrosterone (DHEA) or growth hormone within 12&#xD;
             weeks prior to study entry.&#xD;
&#xD;
          -  Take hydroxyurea within 30 days of study entry.&#xD;
&#xD;
          -  Take drugs for diabetes.&#xD;
&#xD;
          -  Have diabetes.&#xD;
&#xD;
          -  Take granulocyte-macrophage colony-stimulating factor (GM-CSF). (Granulocyte&#xD;
             colony-stimulating factor (G-CSF) is allowed.)&#xD;
&#xD;
          -  Take cytokines, cytokine inhibitors, or ketoconazole.&#xD;
&#xD;
          -  Take ritonavir with simvastatin or lovastatin.&#xD;
&#xD;
          -  Have an active opportunistic infection. Patients on treatment for at least 12 weeks&#xD;
             will be allowed.&#xD;
&#xD;
          -  Have 5-7 loose stools per day or diarrhea for more than 1 week, within 6 weeks of&#xD;
             study entry.&#xD;
&#xD;
          -  Have a blood pressure greater than 160 over 100.&#xD;
&#xD;
          -  Have certain heart problems.&#xD;
&#xD;
          -  Have a breast mass that has not been diagnosed.&#xD;
&#xD;
          -  Have active cancer.&#xD;
&#xD;
          -  Have had prostate cancer or certain other prostate problems.&#xD;
&#xD;
          -  Are allergic to any part of the testosterone gel.&#xD;
&#xD;
          -  Have a history of blood clots.&#xD;
&#xD;
          -  Have a history of sleep apnea.&#xD;
&#xD;
          -  Are receiving experimental treatment.&#xD;
&#xD;
          -  Are receiving experimental drugs in other studies and do not know if they are taking&#xD;
             the drug or placebo.&#xD;
&#xD;
          -  Abuse drugs or alcohol in a way that would interfere with the study.&#xD;
&#xD;
          -  Are dieting or doing heavy exercising.&#xD;
&#xD;
          -  Have a viral load of 10,000 copies/ml or more at screening&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalender Bhasin</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Cecilia Shikuma</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>USC CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900331079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles R. Drew Univ. of Medicine and Science, Div. of Infectious Diseases</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford CRS</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>943055107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd, Avrc Crs</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Med. Ctr.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Mateo County AIDS Program</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marin County Dept. of Health &amp; Human Services, HIV/AIDS Program &amp; Specialty Clinic</name>
      <address>
        <city>San Rafael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Med. Ctr.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Hawaii at Manoa, Leahi Hosp.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>462025250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Wishard Memorial</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hosp. of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHV Baltimore Treatment CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, ACTU</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455-0392</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis ConnectCare, Infectious Diseases Clinic</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. of the Univ. of Pennsylvania CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Pennsylvania Health System, Presbyterian Med. Ctr.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitt CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico-AIDS CRS</name>
      <address>
        <city>San Juan</city>
        <zip>009365067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 1, 2001</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>Anthropometry</keyword>
  <keyword>Obesity</keyword>
  <keyword>Abdomen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

